News & Updates
Showing Hepatology articles
Showing
HBsAg seroclearance tied to lower recurrence risk of HBV-related hepatocellular carcinoma
Hepatitis B surface antigen (HBsAg) seroclearance appears to reduce the risk of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) late recurrence among patients who underwent curative liver resection, results of a Korea study have shown.
HBsAg seroclearance tied to lower recurrence risk of HBV-related hepatocellular carcinoma
10 Oct 2022
Intensive weight-loss does not improve outcomes in obese NAFLD patients
An intensive weight-loss intervention has failed to substantially improve the treatment outcomes among obese patients with nonalcoholic fatty liver disease (NAFLD), reports a recent study.
Intensive weight-loss does not improve outcomes in obese NAFLD patients
22 Sep 2022
Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection
Treatment with vebicorvir (VBR) plus nucleos(t)ide reverse transcriptase inhibitors (NrtIs) among virologically suppressed patients with chronic hepatitis B virus (HBV) is well tolerated and has a favourable safety profile, according to a 24-week study.
Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection
16 Sep 2022
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
11 Sep 2022
Inflammatory diet ups NAFLD risk, especially in men
A dietary pattern with high inflammatory potential appears to increase the risk of nonalcoholic fatty liver disease (NAFLD), reports a study, adding that this association is greater in men.
